FINWIRES · TerminalLIVE
FINWIRES

Toromont Industries公佈的第一季獲利和營收均超出預期;公司專注於電力和能源業務

By

-- 托羅蒙特工業公司(TIH.TO)週二晚間公佈的第一季財報顯示,其盈利和營收均超出預期,同時該公司「將繼續考慮投資其電力和能源業務增長的機會」。 截至2026年3月31日的第一季度,該公司淨利為9,270萬美元,即每股攤薄收益1.13美元,而去年同期為7,444萬美元,即每股攤薄收益0.91美元。該業績高於FactSet匯總的每股1.07美元的普遍預期。 該季度營收成長至近12.3億美元,去年同期為10.9億美元。該業績也高於普遍預期的11.725億美元。 「儘管全球貿易市場持續存在不確定性,但我們的團隊在本季度表現出色,」總裁兼首席執行官邁克爾·S·麥克米蘭表示,「營收和利潤均有所增長,反映出公司大部分業務領域的良好執行。設備集團的新舊設備銷售額均實現穩健增長,租賃和產品支持業務也表現良好。我們的AVL機櫃業務持續增產,主要滿足美國東部地區數據中心的需求。 麥克米蘭表示,基於營運績效和市場需求,公司將繼續考慮投資電力和能源業務成長的機會。 因此,自今日起,公司透過提前收購目前尚未持有的AVL股份的一半,將其持股比例提高至80%。公告指出,此次收購的股份由一位被動投資者持有,不會影響AVL總裁Vince DiCristofaro的持股或地位。此次股份收購價格為7,100萬美元,以現金支付,預計將在2026年第二季計入約4,500萬美元的費用。 公司董事會也批准了每股0.56美元的季度股息,將於7月2日支付給截至6月5日營業結束時登記在冊的股東。上月季度股息已調高7.7%至每股0.56美元。 週二,該公司股票在多倫多證券交易所收盤下跌1%,以208.86美元。

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS